NanoViricides Provides An Update On Its Clinical Program And Strategy In Its Letter To Shareholder, Says NV-387, An Antiviral Drug, Could Be As Revolutionary As Antibiotics
NanoViricides Provides An Update On Its Clinical Program And Strategy In Its Letter To Shareholder, Says NV-387, An Antiviral Drug, Could Be As Revolutionary As Antibiotics
Nanoviricides在致股東的信中提供了其臨床計劃和策略的更新,表示NV-387,一種抗病毒藥物,可能與抗生素一樣具有革命性。
NanoViricides Provides An Update On Its Clinical Program And Strategy In Its Letter To Shareholder, Says NV-387, An Antiviral Drug, Could Be As Revolutionary As Antibiotics
Nanoviricides在致股東的信中提供了其臨床計劃和策略的更新,表示NV-387,一種抗病毒藥物,可能與抗生素一樣具有革命性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。